United Therapeutics Corporation (NASDAQ:UTHR) is scheduled to be posting its quarterly earnings results before the market opens on Wednesday, July 26th. Analysts expect United Therapeutics Corporation to post earnings of $3.65 per share for the quarter.

United Therapeutics Corporation (NASDAQ:UTHR) last released its quarterly earnings results on Wednesday, April 26th. The biotechnology company reported $3.89 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.12 by $0.77. United Therapeutics Corporation had a net margin of 41.04% and a return on equity of 34.74%. The firm had revenue of $370.50 million during the quarter, compared to analyst estimates of $399.59 million. During the same quarter last year, the business earned $3.02 EPS. The company’s revenue was up .4% compared to the same quarter last year. On average, analysts expect United Therapeutics Corporation to post $14.46 EPS for the current fiscal year and $10.98 EPS for the next fiscal year.

United Therapeutics Corporation (NASDAQ UTHR) opened at 129.96 on Wednesday. The firm’s 50-day moving average is $129.77 and its 200 day moving average is $137.45. United Therapeutics Corporation has a 12-month low of $110.72 and a 12-month high of $169.89. The company has a market cap of $5.86 billion, a price-to-earnings ratio of 9.13 and a beta of 1.52.

United Therapeutics Corporation announced that its Board of Directors has approved a share repurchase program on Thursday, April 27th that allows the company to repurchase $250.00 million in shares. This repurchase authorization allows the biotechnology company to buy up to 4.6% of its shares through open market purchases. Shares repurchase programs are usually a sign that the company’s leadership believes its stock is undervalued.

A number of brokerages recently commented on UTHR. UBS Group AG began coverage on United Therapeutics Corporation in a research note on Wednesday, March 29th. They issued a “sell” rating and a $112.00 price target for the company. Cowen and Company lowered United Therapeutics Corporation from an “outperform” rating to a “market perform” rating and dropped their price target for the stock from $140.00 to $121.00 in a research note on Monday, April 3rd. HC Wainwright reaffirmed a “hold” rating and issued a $95.00 price target on shares of United Therapeutics Corporation in a research note on Monday, April 17th. Jefferies Group LLC reaffirmed a “sell” rating and issued a $116.00 price target on shares of United Therapeutics Corporation in a research note on Wednesday, April 12th. Finally, Wedbush reaffirmed an “outperform” rating and issued a $213.00 price target (down previously from $229.00) on shares of United Therapeutics Corporation in a research note on Thursday, April 27th. Five investment analysts have rated the stock with a sell rating, eight have issued a hold rating, two have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and an average target price of $134.50.

In other news, CEO Martine A. Rothblatt sold 1,238 shares of the firm’s stock in a transaction on Thursday, July 13th. The stock was sold at an average price of $130.44, for a total transaction of $161,484.72. Following the completion of the transaction, the chief executive officer now directly owns 1,378 shares in the company, valued at $179,746.32. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Raymond Dwek sold 3,490 shares of the firm’s stock in a transaction on Friday, June 23rd. The shares were sold at an average price of $131.71, for a total value of $459,667.90. The disclosure for this sale can be found here. In the last quarter, insiders sold 23,807 shares of company stock valued at $3,039,475. 7.80% of the stock is owned by corporate insiders.

WARNING: “United Therapeutics Corporation (NASDAQ:UTHR) to Release Quarterly Earnings on Wednesday” was originally published by American Banking News and is the property of of American Banking News. If you are reading this story on another domain, it was copied illegally and republished in violation of US & international trademark & copyright laws. The legal version of this story can be read at https://www.americanbankingnews.com/2017/07/19/united-therapeutics-corporation-nasdaquthr-to-release-quarterly-earnings-on-wednesday.html.

United Therapeutics Corporation Company Profile

United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Company markets and sells four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH): Remodulin (treprostinil) Injection; Tyvaso (treprostinil) Inhalation Solution (Tyvaso); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca).

Earnings History for United Therapeutics Corporation (NASDAQ:UTHR)

Receive News & Ratings for United Therapeutics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics Corporation and related companies with MarketBeat.com's FREE daily email newsletter.